Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Grand Pharmaceutical Group Limited
遠大醫藥集團有限公司*
(Incorporated in Bermuda with limited liability)
(Stock Code: 00512)

VOLUNTARY ANNOUNCEMENT

THE REGISTRATION CLINICAL STUDY CONDUCTED IN CHINA OF THE GLOBAL INNOVATIVE TEMPERATURE-SENSITIVE EMBOLIC AGENT HAS COMPLETED ALL PATIENTS ENROLLMENT

This announcement is made by the board of directors (the "**Board**") of Grand Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board is pleased to announce that the registration clinical study conducted in China of GPN00289, a global innovative temperature-sensitive embolic agent product of the Group, for transarterial chemoembolization of primary liver cancer has completed all patients' enrollment recently. The study is a prospective, multi-center, randomized, parallel-controlled clinical study. It aims to evaluate the safety and effectiveness of GPN00289 for transarterial chemoembolization of primary liver cancer. The completion of all patients' enrolment in the registration clinical study of GPN00289 is another major R&D progress of the Group in the direction of tumor intervention in the field of nuclear medicine anti-tumor diagnosis and treatment.

GPN00289 is a temperature sensitive embolic material that granted innovative medical device qualification certification by the National Medical Products Administration of China ("**NMPA**") for the treatment of hypervascular benign and malignant tumors. The product has the characteristics of temperature response and high plasticity. It can undergo liquid-solid phase transition with changes in temperature, and can embolize blood vessels of different sizes and shapes. The product has good fluidity at the room temperature. After being transported to the blood vessels of the diseased tissue through the microcatheter, in-situ solidification from the peripheral blood vessels to the main supply blood vessels is formed at human body temperature, thereby achieve complete embolization of the peripheral blood vessels of the diseased tissue. It can effectively prevent the formation of collateral circulation, block arterial blood flow more completely, permanently and effectively, and is suitable for embolization treatment of various hypervascular parenchymal organ tumors, especially the embolization therapy for benign and malignant tumors of the hypervascular liver. At the same time, the product has degradable properties, allowing blood vessels to receive multiple treatment opportunities and reducing

adverse reactions caused by persistent embolism. It is highly safe and can be developed instantly to meet the needs of precise surgical operations.

According to the data from GLOBOCAN 2022, there are approximately 870,000 new cases of liver cancer worldwide, ranking sixth among tumors; and approximately 760,000 deaths, ranking third. The 2024 National Cancer Report of the National Cancer Center of China shows that in 2022, there were approximately 370,000 new cases of liver cancer in China (accounting for 42.5% of the world), ranking fourth among tumors; there were approximately 320,000 deaths (accounting for 42.1% of the world), ranking second; and the proportions ranked first in the world. Surgical resection is the preferred method for treating early liver cancer, but because liver cancer is insidious, early symptoms are not obvious or typical, its early diagnosis is difficult, less than 30% of liver cancer patients are suitable for radical treatment at the initial diagnosis, and treatment is difficult, so the prognosis is poor, and the ratio of morbidity to mortality is as high as 1: (0.8-0.9); even with radical resection, the 5-year tumor recurrence and metastasis rate after liver cancer resection is as high as 50% to 70%; the 5-year survival rate in North American countries and regions is less than 20%, and it is even lower in China at only 12%. Therefore, liver cancer patients are in urgent need of effective treatment. The most classic clinical treatment for patients with advanced liver cancer is transcatheter arterial chemoembolization ("**TACE**"). Conventional TACE is mainly divided into liquid embolization based on iodized oil chemotherapy drug emulsion and solid embolization based on particle-type embolic agents. Solid embolization has good embolization effect, but it is difficult to enter the peripheral blood vessels. While liquid embolism can embolize peripheral blood vessels, it will be quickly cleared in the body and cannot release drugs slowly. These defects will affect the effect of TACE in the treatment of liver cancer. GPN00289 combines the advantages of liquid embolism and solid embolism, integrating drug loading and embolization into one, which can make up for the defects of existing TACE treatment methods.

At the same time, based on the drug-carrying function of GPN00289, in addition to being used in combination with existing chemotherapy drugs, it is also expected to be used in combination with the Group's global innovative internal radiotherapy drug, YiGanTai Y-90 microsphere injections. On the one hand, it can further enhance the products' therapeutic effect on liver cancer, and on the other hand, it is expected to further expand the potential indications of YiGanTai Y-90 microsphere injections.

The Group holds global rights to GPN00289. The product has entered the registered clinical trial research stage in China in July 2024, and completed the first patient enrollment in December 2024. In the future, the Group will actively advance the global registrational development of GPN00289 and strive to strategically integrate the product with Yigantai Y-90 microsphere injections in both the Chinese and overseas markets to create product synergies, continue to deepen technological innovation in the field of global liver cancer treatment, and further deepen the Group's industrial strategic plan in the nuclear medicine anti-tumor diagnosis and treatment segment.

In the nuclear medicine anti-tumor diagnosis and treatment segment, the Group has achieved a comprehensive layout in the fields of R&D, production, distribution, and sales, with over 900 employees worldwide. The Group has established a global nuclear medicine industry chain layout based on its R&D centers in Boston and Chengdu, production facilities in Boston, Frankfurt, Singapore, and Chengdu, and a sales network covering over 50 countries and regions worldwide.

The Group, together with Sirtex Medical Pty Ltd, cooperated with Telix Pharmaceutical Limited and ITM Isotope Technologies Munich SE to establish a world-class tumor intervention technology platform and a radionuclide-drug conjugate ("**RDC**") technology platform. The Group adheres to the treatment concept of integrated oncology diagnosis and treatment. Currently, the Group has 15 innovative products in the pipeline at the R&D registration stage, covering five radionuclides including ^{68}Ga, ^{177}Lu, ^{131}I, ^{90}Y, ^{89}Zr as well as seven cancers including liver cancer, prostate cancer and brain cancer. The early stages of R&D focused primarily on RDC drugs, with a product pipeline now comprising 12 products. In terms of product types, it covers two types of radionuclide drugs for diagnosis and therapy, providing patients with global leading anti-tumor solutions with multi-indication treatment options, multi-means and integrated diagnosis and treatment.

Global R&D efforts for innovative products within the segment are progressing smoothly. In China, YiGanTai® Y-90 microsphere injection was successfully launched in January 2022 for the treatment of liver metastases from colorectal cancer, and in May 2025, it received approval from the NMPA to conduct a Phase II registrational clinical trial for the treatment of unresectable hepatocellular carcinoma (HCC); The global innovative temperature-sensitive embolization agent GPN00289 completed the first patient enrollment in its registrational clinical study in December 2024. Overseas registration-wise, SIR-Spheres® Y-90 microsphere injection was formally approved in the United States for a new indication, used to treat unresectable HCC, marking SIR-Spheres® Y-90 resin microsphere injection as the first and only FDA-approved selective internal radiation therapy for the dual indications of unresectable HCC and colorectal liver metastases; granted CE Mark approval in Europe for multiple liver cancer indications in September 2025, further promote the full coverage of the product in the treatment of unresectable liver cancer and achieve market expansion at a strategic level, meanwhile, it demonstrates the Group's excellent overseas clinical registration capabilities and commercial operation capabilities, providing significant safeguards for the subsequent global development of self-developed innovative nuclear medicine products, at the same time, relevant overseas clinical data will also provide key support for the expansion of liver cancer-related indications of the product in China; in addition, the Group is also actively collaborating with Chinese and international experts to develop other indications for SIR-Spheres® Y-90 resin microsphere injection. The Group will adopt an international registration pathway involving dual filings in China and the United States to facilitate global market expansion for the product. At present, the Group has 5 RDC drugs approved to conduct registered clinical research in the nuclear medicine anti-tumor diagnosis and treatment segment, with 4 of them having entered the Phase III clinical stage, including TLX591-CDx for diagnosing prostate cancer, TLX591 for treating prostate cancer, TLX250-CDx for diagnosing clear cell renal cell carcinoma, and ITM-11 for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In addition, global innovative diagnostic radiopharmaceutical GPN02006, which targets glypican-3 ("**GPC-3**") based on radionuclide-antibody conjugation technology, has achieved a milestone breakthrough in the investigator-initiated clinical study (IIT clinical study) conducted in China earlier, and granted an oral presentation at the 2025 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI); clinical research data showed that GPN02006 exhibited excellent safety and imaging efficacy: all subjects did not report any drug-related adverse reactions after administration, and the safety and tolerability performance was excellent; high-quality imaging can be achieved 30 minutes after administration, fully meeting the clinical rapid diagnosis needs of hepatocellular carcinoma. GPN02006 has great potential and is expected to become the world's first hepatocellular carcinoma (HCC) diagnostic RDC product targeting the GPC-3 target. As for now, the Group has the largest total reserve of innovative diagnostic and therapeutic RDC drugs that have entered Phase III clinical studies in China, and also one of the innovative pharmaceutical companies in the world with the richest product pipeline and integrated diagnosis and treatment strategic plan in the field of

nuclear medicine anti-tumor.

Grand Pharma's Radiopharmaceutical R&D and Production Base（遠大醫藥放射性藥物研發及生產基地）, located in Wenjiang District, Chengdu, Sichuan Province, China, was completed and accepted in April 2025, obtained a Class A Radiation Safety Licence issued by the Ministry of Ecology and Environment in May, and officially commenced operations at the end of June. This facility is the world's first fully integrated closed-loop nuclear medicine supply chain platform, covering the entire value chain from "isotope production – nuclear medicine R&D – manufacturing – clinical trials – commercialization". It has established endto-end management capabilities spanning the entire lifecycle from early-stage R&D to clinical translation to commercialization, with R&D efficiency leading globally. It addresses the 'bottleneck' challenges in nuclear medicine, achieving 100% domestic production to break free from reliance on imports. Fourteen high-standard GMP production lines meet the demand for multi-product, large-scale production. Established a fully intelligent management system, featuring nuclear-grade safety and unmanned intelligent manufacturing, achieving "zero radiation leakage", "zero pollution discharge", and "zero occupational exposure exceeding standards", meeting the standards of the world's top nuclear facilities. We have established a world-class research, production, quality, and operational system, making it one of the most comprehensive and highly automated intelligent factories in the world in terms of isotope variety and automation levels. This R&D and production base will further solidify the foundation of the Group's nuclear pharmaceutical industry, accelerate the implementation of global innovative R&D pipelines, drive the Group's high-quality development in the nuclear pharmaceutical sector, cultivate high-value blockbuster products, and lay a solid foundation for the domestic production of the Group's radioactive drugs. In the future, the Group will continue to strengthen the R&D in and establishment of the nuclear medicine anti-tumor diagnosis and treatment segment, as well as enrich and improve the product pipeline and industrial layout, forming a nuclear medicine anti-tumor diagnosis and treatment product cluster with the core of YiGanTai® Y-90 resin microsphere injections, which continuously consolidates the Group's global leading position in the field of nuclear medicine anti-tumor diagnosis and treatment.

The Group always puts focus on the R&D of innovative products and advanced technologies. Adhering to a patient-centered and innovation-driven approach, the Group will continue to increase its investment in world-class innovative products and advanced technologies to meet unmet clinical needs and enrich its product pipeline and improve supply chain. The Group adopts the strategy of "global expansion and dual-cycle operation", forming a new pattern of domestic and international cycles that synergize with each other. In this way, the Group can make full use of its industrial advantages and R&D capabilities, to accelerate the commercialization process for innovative products and provide patients with more advanced and diverse treatment options globally.

Warning:

The aforementioned product is still in the R&D stage. The approval of commercialization, manufacturing and sale of such product is subject to various factors with uncertainty, and whether it can ultimately benefit is still uncertain. Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company

Note: The English transliteration of the Chinese name(s) in this announcement is included for information purpose only, and should not be regarded as the official English name(s) of such Chinese name(s).

By order of the Board
Grand Pharmaceutical Group Limited
Chairman
Dr. Tang Weikun

Hong Kong, 9 October 2025

As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Mr. Zhou Chao, Mr. Yang Guang and Ms. Lam Chit Yee Jessica, and four independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Xing Li Na, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*